Jyong Biotech (NASDAQ:MENS) Trading 6.5% Higher - What's Next?

Key Points

• Jyong Biotech Ltd. (NASDAQ:MENS) shares rose by 6.5% to last trade at $41.94, despite a significant drop in trading volume, which was 85% lower than the average session.
• Wall Street Zen upgraded Jyong Biotech shares to a "hold" rating on June 30th, indicating a more cautious outlook for investors.
• The company's stock has seen a 22.5% increase over recent periods, with a 50-day moving average currently at $44.21.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares shot up 6.5% on Wednesday . The company traded as high as $42.55 and last traded at $41.94. 32,925 shares traded hands during trading, a decline of 85% from the average session volume of 224,532 shares. The stock had previously closed at $39.38.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Jyong Biotech to a "hold" rating in a report on Monday, June 30th.

Jyong Biotech Stock Up 22.5%

The firm has a 50 day moving average of $44.21.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.